M&A Deal Summary

Melinta Therapeutics Acquires The Medicines Company - Infectious Disease Business

On November 29, 2017, Melinta Therapeutics acquired life science company The Medicines Company - Infectious Disease Business from The Medicines Company for 270M USD

Acquisition Highlights
  • This is Melinta Therapeutics’ 1st transaction in the Life Science sector.
  • This is Melinta Therapeutics’ largest (disclosed) transaction.
  • This is Melinta Therapeutics’ 1st transaction in the United States.
  • This is Melinta Therapeutics’ 1st transaction in New Jersey.

M&A Deal Summary
Date 2017-11-29
Target The Medicines Company - Infectious Disease Business
Sector Life Science
Buyer(s) Melinta Therapeutics
Sellers(s) The Medicines Company
Deal Type Divestiture
Deal Value 270M USD

Target

The Medicines Company - Infectious Disease Business

Parsippany, New Jersey, United States
The Medicines Company - Infectious Disease Business includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline).

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Melinta Therapeutics

New Haven, Connecticut, United States
Category Company
Sector Life Science
DESCRIPTION

Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-02-05 Melinta Therapeutics - Fusidic Acid

New Haven, Connecticut, United States

Melinta Therapeutics, Inc. - Fusidic Acid is an antibiotic that is often used topically in creams and eyedrops but may also be given systemically as tablets or injections.

Sell -

Seller(S) 1

SELLER

The Medicines Company

Parsippany, New Jersey, United States
Category Company
Founded 1996
Sector Life Science
Employees62
Revenue 6M USD (2018)
DESCRIPTION
Entrance to The Medicines Company's corporate headquarters in Parsippany, New Jersey.
Entrance to The Medicines Company's corporate headquarters in Parsippany, New Jersey.

The Medicines Company is a provider of solutions in acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The Medicines Company was formed in 1996 and is based in Parsippany, New Jersey. The Medicines was founded in 1996 and is based in Parsippany, New Jersey.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
State (New Jersey) 1 of 1
Country (United States) 2 of 2
Year (2017) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-18 Medicines Company - Hemostasis Products

United States

Medicines Company - Hemostasis Products are RECOTHROM Thrombin topical (Recombinant), PreveLeak, and RAPLIXA (fibrin sealant) products used for blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques.

Sell $175M
Mergr

Product

Company

Legal